Food allergy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Food allergy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Omalizumab monotherapy for patients with vegetable (plant‑based food) allergy due to LTP and profilin sensitization https://clinicaltrials.eu/trial/omalizumab-monotherapy-for-patients-with-vegetable-plant-based-food-allergy-due-to-ltp-and-profilin-sensitization/ Wed, 27 May 2026 09:46:30 +0000 https://clinicaltrials.eu/trial/omalizumab-monotherapy-for-patients-with-vegetable-plant-based-food-allergy-due-to-ltp-and-profilin-sensitization/ The study focuses on people who have a food allergy to plant‑based foods such as peach, melon, or other vegetables. In these individuals the immune system reacts to tiny proteins called LTP (lipid transfer protein) and profilin, which can cause symptoms ranging from mild itching to serious reactions. The treatment being tested is a medication called omalizumab, which is given as an injection under the skin and is intended to calm the allergic response.

The purpose of the study is to see whether a 16‑week course of omalizumab can make it possible for participants to eat larger amounts of the foods that previously triggered their allergy and to improve their overall quality of life. Participants will receive the medication at regular visits, and during the study they will be asked to try small portions of the problematic foods under medical supervision to check for any reaction. Information about how they feel and any changes in their ability to tolerate the foods will be recorded throughout the trial.

]]> Study of DBV712 skin patch safety in children aged 1-3 years with peanut allergy https://clinicaltrials.eu/trial/study-of-dbv712-skin-patch-safety-in-children-aged-1-3-years-with-peanut-allergy/ Wed, 29 Apr 2026 15:07:37 +0000 https://clinicaltrials.eu/trial/study-of-dbv712-skin-patch-safety-in-children-aged-1-3-years-with-peanut-allergy/ This study focuses on children aged 1-3 years with peanut allergy. The main treatment being tested is Viaskin Peanut (DBV712), which is a special patch containing peanut extract that is placed on the skin. This treatment method is called epicutaneous immunotherapy, meaning it delivers the treatment through the skin. The study will compare the treatment patch containing 250 micrograms of peanut extract against a placebo patch that looks the same but contains no peanut proteins.

The purpose of this research is to evaluate how safe the peanut patch treatment is when used for 6 months in very young children with peanut allergy. During the study, participants will also undergo skin prick tests using special solutions to check their allergic responses. They will receive either the active treatment patch or placebo patch, which needs to be applied to the skin daily.

The study will track various safety aspects, including any reactions at the patch site and other health effects. Researchers will also monitor changes in the body’s immune response to peanuts by measuring specific antibodies in the blood and conducting skin tests. The treatment period will last for 24 months, during which participants will be regularly monitored for any side effects or allergic reactions.

]]> Study on Long-term Benefits and Safety of DBV712 for Children with Peanut Allergy https://clinicaltrials.eu/trial/study-on-long-term-benefits-and-safety-of-dbv712-for-children-with-peanut-allergy/ Wed, 29 Apr 2026 14:59:24 +0000 https://clinicaltrials.eu/trial/study-on-long-term-benefits-and-safety-of-dbv712-for-children-with-peanut-allergy/ This clinical trial is focused on studying peanut allergy in children. The trial will use a treatment called Viaskin Peanut, which is a patch applied to the skin. The patch contains a small amount of peanut extract and is designed to help children with peanut allergies become less sensitive to peanuts over time. The study will also involve an oral paste made from peanut flour in different doses, including a low dose, a high dose, and a placebo, which is a substance with no active ingredient.

The purpose of the study is to evaluate the long-term benefits and safety of using Viaskin Peanut for up to three years. Children participating in the study will receive the treatment and be monitored to see if they become less sensitive to peanuts. The study will also check for any side effects or reactions to the treatment. The children will be given the treatment over a period of time, and their response to peanuts will be tested at different stages to see if the treatment is effective.

Throughout the study, researchers will collect information on how well the children tolerate peanuts and any changes in their allergy symptoms. The study aims to help understand if this treatment can provide a long-term solution for children with peanut allergies, making it safer for them to be around peanuts without having severe allergic reactions. The study will also look at the overall health and quality of life of the children during the treatment period.

]]> Study on the Safety and Tolerability of INP20 for Peanut Allergy in Patients https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-inp20-for-peanut-allergy-in-patients/ Wed, 29 Apr 2026 14:58:24 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-inp20-for-peanut-allergy-in-patients/ This clinical trial is focused on studying a condition known as peanut allergy. The trial is testing a new treatment called INP20, which is an oral formulation made from peanut extract nanoparticles. The purpose of the study is to determine the safety, tolerability, and potential effectiveness of INP20 in people who are allergic to peanuts. The study will also help find the best dose of INP20 for treating peanut allergies.

The study is divided into two parts. In the first part, participants will receive different doses of INP20 to find the most suitable dose that is safe and well-tolerated. This part will help identify the maximum dose that can be given without causing significant side effects. In the second part, participants will receive the recommended dose of INP20 for a period of six months to further evaluate its safety and tolerability. Throughout the study, some participants will receive a placebo to compare the effects of INP20 against no active treatment.

Participants in the study will be monitored for any allergic reactions or side effects. The study will also measure changes in the immune response to peanuts, including levels of specific antibodies like IgE and IgG4, which are proteins in the blood that play a role in allergic reactions. The goal is to see if INP20 can help increase the amount of peanut protein that participants can consume without experiencing an allergic reaction. This study aims to provide valuable information on a potential new treatment for managing peanut allergies.

]]> Study on the Safety and Effectiveness of Low-Dose Oral Immunotherapy with Omalizumab for Children with Severe Cow’s Milk Allergy https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-low-dose-oral-immunotherapy-with-omalizumab-for-children-with-severe-cows-milk-allergy/ Wed, 29 Apr 2026 14:26:55 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-low-dose-oral-immunotherapy-with-omalizumab-for-children-with-severe-cows-milk-allergy/ This clinical trial is focused on children with a severe allergy to cow’s milk, specifically an IgE-mediated cow’s milk allergy. The study is investigating the use of a treatment called Omalizumab, which is a medication given as an injection. Omalizumab is known to help manage allergies by targeting a specific protein in the body that plays a role in allergic reactions. The study will also involve a process called oral immunotherapy, where small amounts of milk are gradually introduced to the child’s diet to help build tolerance.

The purpose of the study is to analyze the safety and effectiveness of combining low-dose oral immunotherapy with Omalizumab in children with severe cow’s milk allergy. During the study, participants will receive injections of Omalizumab and will be exposed to small amounts of milk under medical supervision. The study will monitor how well the children tolerate the milk and whether the treatment helps reduce allergic reactions over time.

The study will last for a period of up to 18 months. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to assess the effectiveness of the treatment. The goal is to see if the combination of Omalizumab and oral immunotherapy can help children with severe cow’s milk allergy tolerate milk better and experience fewer allergic reactions.

]]> Study on the Effectiveness and Safety of DBV712 for Peanut Allergy in Children Aged 4-7 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-dbv712-for-peanut-allergy-in-children-aged-4-7/ Wed, 29 Apr 2026 14:23:56 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-dbv712-for-peanut-allergy-in-children-aged-4-7/ This clinical trial is focused on studying a treatment for children aged 4 to 7 years who have a peanut allergy. The treatment being tested is called Viaskin Peanut, also known by its code name DBV712. It is a small patch that is placed on the skin to help the body become less sensitive to peanuts over time. The purpose of the study is to see if this treatment can safely help children with peanut allergies become less sensitive to peanuts.

During the study, children will wear the Viaskin Peanut patch for a period of 12 months. The study will compare the effects of the patch to a placebo, which looks like the patch but does not contain any peanut proteins. The children will be monitored to see if they can tolerate more peanuts after the treatment than they could before. The study will also check for any side effects or reactions to the treatment.

In addition to the Viaskin Peanut patch, the study will use other products to help measure the children’s reactions to peanuts. These include a solution for skin-prick tests and a peanut challenge meal, which are used to test how sensitive the children are to peanuts. The study aims to provide valuable information on the safety and effectiveness of the Viaskin Peanut treatment for children with peanut allergies.

]]> Study on Long-Term Safety of Ligelizumab for Patients with Food Allergies https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ligelizumab-for-patients-with-food-allergies/ Wed, 29 Apr 2026 14:23:28 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ligelizumab-for-patients-with-food-allergies/ This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called ligelizumab for individuals with food allergy. Food allergy is a condition where certain foods trigger an abnormal immune response, leading to symptoms that can range from mild to severe. The study aims to understand how well ligelizumab works over an extended period and how safe it is for patients who have already participated in previous studies involving this treatment.

Participants in this study will receive ligelizumab, which is administered as a solution for injection. The study will also include a comparison with a placebo to evaluate the treatment’s effects. Additionally, some participants may receive other medications such as salbutamol, which is used for inhalation, and epinephrine, which is given as an injection. Another treatment being studied is PCM001, which is a granule form for oral suspension made from defatted peanut powder. These treatments are part of the study to assess their role in managing food allergies.

The study will take place over several years, during which participants will attend regular visits to receive their treatments and undergo assessments. These assessments will help researchers gather information on how well the treatments are tolerated and their impact on food allergy symptoms. The goal is to provide valuable insights into the long-term management of food allergies using ligelizumab and other related treatments.

]]>